此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer (TREVI-OC-03)

2026年9月7日 更新者:AstraZeneca

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)

研究概览

研究类型

介入性

注册 (估计的)

600

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Beijing、中国、100210
        • Research Site
      • Guangdong Province、中国、510060
        • Research Site
      • Guangzhou、中国、510060
        • Research Site
      • Wuhan、中国、430030
        • Research Site
    • British Columbia
      • Abbotsford British Columbia、British Columbia、加拿大、V2S0C2
        • Research Site
    • Quebec
      • Montreal、Quebec、加拿大、H3A 1A1
        • Research Site
      • Montreal、Quebec、加拿大、H2X 0A9
        • Research Site
      • Ahmedabad、印度、380060
        • Research Site
      • Bangalore、印度、560004
        • Research Site
      • Gurgaon、印度、122002
        • Research Site
      • Kottayam、印度、686008
        • Research Site
      • Madurai、印度、625107
        • Research Site
      • Nashik、印度、422002
        • Research Site
      • Nashik、印度、422 009
        • Research Site
      • New Delhi、印度、11029
        • Research Site
      • Vadodara、印度、391760
        • Research Site
      • Kaohsiung City、台湾、81362
        • Research Site
      • Taichung、台湾、40705
        • Research Site
      • Taichung、台湾、40447
        • Research Site
      • Tainan、台湾、70403
        • Research Site
      • Taipei、台湾、10449
        • Research Site
      • Porto Alegre、巴西、90035903
        • Research Site
      • São Caetano do Sul、巴西、09541-270
        • Research Site
      • São José do Rio Preto、巴西、15090-000
        • Research Site
      • São José dos Campos、巴西、12210-030
        • Research Site
      • São Paulo、巴西、01327-001
        • Research Site
      • Teresina、巴西、64049-200
        • Research Site
      • Vitória、巴西、29043-260
        • Research Site
      • Bad Homburg、德国、61352
        • Research Site
      • Bonn、德国、53127
        • Research Site
      • Brandenburg、德国、14770
        • Research Site
      • Gütersloh、德国、33332
        • Research Site
      • Homburg、德国、66421
        • Research Site
      • Kassel、德国、34125
        • Research Site
      • Mainz、德国、55131
        • Research Site
      • Mannheim、德国、68167
        • Research Site
      • Wiesbaden、德国、65189
        • Research Site
      • Fukuoka、日本、812-8582
        • Research Site
      • Fukushima、日本、960-1295
        • Research Site
      • Kobe、日本、650-0047
        • Research Site
      • Kyoto、日本、612-8555
        • Research Site
      • Kōtoku、日本、135-8550
        • Research Site
      • Minatoku、日本、105-8471
        • Research Site
      • Natori-shi、日本、981-1293
        • Research Site
      • Sagamihara-shi、日本、252-0375
        • Research Site
      • Shinjuku-ku、日本、160-0023
        • Research Site
      • Suita-shi、日本、565-0871
        • Research Site
      • Toyoake-shi、日本、470-1192
        • Research Site
      • Yokohama、日本、236-0004
        • Research Site
      • Bangkok、泰国、10210
        • Research Site
      • Bangkok、泰国、10330
        • Research Site
      • Bangkok、泰国、10700
        • Research Site
      • Hat Yai、泰国、90110
        • Research Site
      • Muang、泰国、50200
        • Research Site
      • Auchenflower、澳大利亚、4066
        • Research Site
      • Blacktown、澳大利亚、2148
        • Research Site
      • Clayton、澳大利亚、3168
        • Research Site
      • Liverpool、澳大利亚、2170
        • Research Site
    • Alaska
      • Anchorage、Alaska、美国、99508
        • Research Site
    • Maryland
      • Columbia、Maryland、美国、21044
        • Research Site
    • Michigan
      • Detroit、Michigan、美国、48201
        • Research Site
    • New York
      • Albany、New York、美国、12206
        • Research Site
      • Bay Shore、New York、美国、11706
        • Research Site
      • Greenlawn、New York、美国、11740
        • Research Site
      • New Hyde Park、New York、美国、11042
        • Research Site
      • New York、New York、美国、10029
        • Research Site
      • Rego Park、New York、美国、11374
        • Research Site
    • Ohio
      • Cleveland、Ohio、美国、44195
        • Research Site
      • Cleveland、Ohio、美国、44111
        • Research Site
      • Columbus、Ohio、美国、43210
        • Research Site
      • Mayfield Heights、Ohio、美国、44124
        • Research Site
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Research Site
      • Willow Grove、Pennsylvania、美国、19090
        • Research Site
    • West Virginia
      • Morgantown、West Virginia、美国、26506
        • Research Site
      • Goyang-si、韩国、10408
        • Research Site
      • Seoul、韩国、03080
        • Research Site
      • Seoul、韩国、03722
        • Research Site
      • Seoul、韩国、135-710
        • Research Site
      • Seoul、韩国、5505
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
  • Provision of an archival FFPE tumour sample
  • Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
  • Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
  • Participants who received at least 6 cycles of PBC during the induction phase of their current line of treatment.
  • Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
  • Participants with non-progressive disease upon completion of PBC in their current line of treatment.
  • Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).

Exclusion Criteria:

  • Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.
  • Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
  • Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab)
  • Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab)
  • Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Torvutatug samrotecan monotherapy or in combination with bevacizumab
Torvutatug samrotecan monotherapy intravenous (IV) or Torvutatug samrotecan IV with bevacizumab IV.
FRa targeting antibody drug conjugate Topoisomerase I inhibitor
其他名称:
  • AZD5335
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor
有源比较器:Observation or bevacizumab
Observation or bevacizumab IV.
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-Free Survival (PFS)
大体时间:Up to approximately 5 years
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by Blinded Independent Central Review, or death due to any cause.
Up to approximately 5 years

次要结果测量

结果测量
措施说明
大体时间
Overall Survival (OS)
大体时间:Up to approximately 5 years
OS is defined as time from randomisation until the date of death due to any cause.
Up to approximately 5 years
Second Progression-Free Survival (PFS2)
大体时间:Up to approximately 5 years
PFS2 is defined as time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression) after first subsequent therapy, or death.
Up to approximately 5 years
Time to First Subsequent Therapy (TFST)
大体时间:Up to approximately 5 years
TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.
Up to approximately 5 years
Time to Second Subsequent Therapy (TSST)
大体时间:Up to approximately 5 years
TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.
Up to approximately 5 years
Health-related Quality of Life (HrQoL)
大体时间:Up to approximately 5 years
Change from baseline and time to deterioration in global health status/quality of life (GHS/QoL), physical functioning (PF), and ovarian cancer symptoms (EORTC IL433).
Up to approximately 5 years
Number and percentage of participants with adverse events as graded by CTCAE v6 criteria
大体时间:Up to approximately 5 years
Adverse Event Incidence
Up to approximately 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月29日

初级完成 (估计的)

2028年9月26日

研究完成 (估计的)

2031年10月27日

研究注册日期

首次提交

2026年9月7日

首先提交符合 QC 标准的

2026年9月7日

首次发布 (实际的)

2026年9月14日

研究记录更新

最后更新发布 (实际的)

2026年9月14日

上次提交的符合 QC 标准的更新

2026年9月7日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD 共享时间框架

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共享访问标准

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅